Enzene is an end-to-end CDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ (FCCM™) platform validated for commercial biologics supply.

We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, Enzene is striving to reduce monoclonal antibody production costs to below $40 per gram by 2025.  Our microbial and mammalian drug substance plants, as well as our sterile fill & finish plant in India are EU-GMP certified.

Key Products and Services

Discovery and Development: Enzene offers comprehensive services from target identification and validation to antibody discovery and engineering. The company also provides custom reagents and assay development solutions, facilitating a streamlined route to market for biologic therapies.

Manufacturing: Utilising both fed-batch processes and the proprietary EnzeneX™ platform, Enzene provides drug substance and drug product manufacturing services. These services are designed to meet current and future needs, ensuring efficiency and scalability in biologics production.

Analytical and CMC Services: The company offers a range of analytical services, including method development, product characterisation, dynamic process screening, bioassay capabilities, and stability studies, ensuring the highest quality standards in product development.

Biologic Modalities: Enzene's expertise encompasses a wide array of biologic modalities, such as monoclonal antibodies, therapeutic recombinant proteins, recombinant enzymes, conjugated therapeutic proteins, bispecific proteins, fusion proteins, synthetic peptides, plasmid DNA (pDNA), and phytopharmaceuticals.

Portfolio and Licensing: Enzene offers exclusive biosimilar licensing opportunities and Adeno-Associated Virus (AAV) kits for gene therapy applications. The company's biosimilar pipeline includes products in various stages of development, from pre-clinical to late stages, providing end-to-end biosimilar development and manufacturing services.

Enzene Biosciences is committed to revolutionising the biopharmaceutical landscape through continuous innovation and technological advancement. By providing integrated CDMO solutions and maintaining a robust pipeline of biosimilars, Enzene strives to bring life-changing medicines to patients swiftly and cost-effectively, thereby making a positive global impact on healthcare.